First, GLP-1 receptor agonists carry an FDA black box warning about thyroid C-cell tumors based on animal studies, and while the clinical relevance in humans remains uncertain, the warning does mean patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take these medications
doi: 10.1073/pnas.1205227109 [DOI] [PMC free article] [PubMed] [Google Scholar] 44.Wilson JM, Lin Y, Luo MJ, et al
Mark Cuban pushes for generic drug fee waivers, as Cost Plus Drugs eyes U.S
The LiveSMART trial demonstrated that lactulose combined with Tai-Chi reduced falls and fall-related injuries in patients with cirrhosis without prior OHE [114]
Abstract Background Retatrutide, a novel GIP, GLP-1, and glucagon receptor triple agonist, exhibits unprecedented weight-reducing efficacy in clinical trials, yet the molecular basis of its systemic metabolic benefits remains unclear
Zepbound Savings Program On February 25, 2025, Eli Lilly announced the expansion of its Zepbound savings program, offering additional vial dose options and new cost-saving opportunities for self-pay patients
